Research At Risk
In the last decade, the EU has committed at least £6.2 million to research projects for pancreatic cancer, vital funding which benefits patients and families in the UK. We simply cannot afford to lose access to European talent, funding, collaboration and clinical trials in the EU negotiations.
Research is the only way to find the game-changing breakthroughs that will transform the future for people with pancreatic cancer.
A recent survey by Pancreatic Cancer UK found that 92% of researchers felt that Brexit could negatively impact access to EU research funding. Read more to find out the summary findings of our survey.
Given that pancreatic cancer research already receives insufficient funding, any reduction in EU funds would significantly limit progress in fighting this disease.